AIPA, OMPA, and ASP14 in vaccine compositions and diagnostic targets for anaplasma phagocytophilum infection

Patent metadata

Field	Value
Publication number	US-10086058-B2
Application number	US-201515115954-A
Country	US
Kind code	B2
Filing date	Jan 30, 2015
Priority date	Feb 3, 2014
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.

First claim

I claim:

1. An immunogenic composition,
wherein said composition comprises a first polypeptide that is or includes one or more copies of SEQ ID NO:14, at least one second polypeptide that is or includes one or more copies of SEQ ID NO:03 and SEQ ID NO:06, and a vehicle or carrier suitable for administration to a subject, or
wherein said composition comprises at least one third polypeptide that includes one or more copies of SEQ ID NO:14 and one or more copies of at least one of SEQ ID NO:03 and SEQ ID NO:06, and a vehicle or carrier suitable for administration to a subject, and
wherein said first and third polypeptide does not include SEQ ID NO: 13.

2. The immunogenic composition of claim 1 , wherein at least one of said first, second, or third polypeptides is linked to one or more of: an amino acid spacer; an amino acid linker; a signal sequence; a stop transfer sequence; a transmembrane domain; a protein purification ligand; a heterologous protein; or one or more additional polypeptides comprising SEQ ID NO:01, 02, 03, 04, 05, 06, 07, 08, 09, 13, or 15.

3. The immunogenic composition of claim 2 , wherein at least one of said first, second, or third polypeptides is linked to said protein purification ligand and said protein purification ligand is selected from the group consisting of glutathione S-transferase (GST) and a histidine tag (His tag).

4. A chimeric protein comprising a polypeptide that is or includes one or more copies of SEQ ID NO:14 and one or more copies of one or more polypeptide sequences, wherein said one or more polypeptide sequences is or includes at least one of SEQ ID NO:03 and SEQ ID NO:06 and wherein said polypeptide does not include SEQ ID NO: 13.

Assignees

• Univ Virginia Commonwealth

Inventors

• Carlyon Jason

Classifications

• G01N2333/195

  from bacteria · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• C07K2319/70

  containing domain for protein-protein interaction · CPC title

• C07K14/29

  from Richettsiales (O) · CPC title